Condition: Hormone Therapy · Sponsor: University of Calgary
1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women. 2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.
This description comes directly from the study's public registry record.
Darlene Y Sola, BScN · 4032107434 · dsola@ucalgary.ca
Victoria Riehl-Tonn, BN · 4032109434 · victoria.riehltonn@ucalgary.ca
Always discuss trial participation with your own doctor first.
| University of Calgary | Calgary, Alberta, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05442463